We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,481 hedge funds and large institutions have $102B invested in Bristol-Myers Squibb in 2023 Q2 according to their latest regulatory filings, with 126 funds opening new positions, 947 increasing their positions, 1,065 reducing their positions, and 163 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $1.43B | Put options by funds: $995M

0.44% less ownership

Funds ownership: 76.44%76% (-0.44%)

2% less funds holding

Funds holding: 2,5412,481 (-60)

8% less capital invested

Capital invested by funds: $111B → $102B (-$8.64B)

11% less repeat investments, than reductions

Existing positions increased: 947 | Existing positions reduced: 1,065

23% less first-time investments, than exits

New positions opened: 126 | Existing positions closed: 163

35% less funds holding in top 10

Funds holding in top 10: 6844 (-24)

Holders
2,481
Holders Change
-60
Holders Change %
-2.36%
% of All Funds
38.95%
Holding in Top 10
44
Holding in Top 10 Change
-24
Holding in Top 10 Change %
-35.29%
% of All Funds
0.69%
New
126
Increased
947
Reduced
1,065
Closed
163
Calls
$1.43B
Puts
$995M
Net Calls
+$431M
Net Calls Change
-$137M
Name Holding Trade Value Shares
Change
Change in
Stake
BCM
951
Brookstone Capital Management
Illinois
$2.05M -$57.1K -852 -3%
PWLP
952
Prio Wealth Limited Partnership
Massachusetts
$2.05M -$26.4K -394 -1%
EB
953
Exchange Bank
California
$2.05M +$2.15M +32,021 New
TSWM
954
Triangle Securities Wealth Management
North Carolina
$2.05M -$31.9K -476 -1%
ET
955
Equitable Trust
Tennessee
$2.05M
PS
956
Pensionfund Sabic
Netherlands
$2.05M
GP
957
Girard Partners
Pennsylvania
$2.04M +$218K +3,253 +11%
MCAI
958
Members Capital Advisors Inc
Wisconsin
$2.03M
BCA
959
Bay Colony Advisors
Massachusetts
$2.02M +$27K +402 +1%
BAM
960
Boyar Asset Management
New York
$2.02M -$8.92K -133 -0.4%
DGAM
961
Desjardins Global Asset Management
Quebec, Canada
$2M +$348K +5,189 +20%
GW
962
GW & Wade
Massachusetts
$2M +$58.9K +879 +3%
RC
963
Roundview Capital
New Jersey
$1.99M -$7.85K -117 -0.4%
LCM
964
Lazari Capital Management
California
$1.99M +$2.09M +31,126 New
RWP
965
RWA Wealth Partners
Massachusetts
$1.99M +$749K +11,167 +56%
LNB
966
Ledyard National Bank
$1.99M -$31.9K -475 -2%
VCM
967
Viewpoint Capital Management
Washington
$1.99M +$12.3K +183 +0.6%
FNBTCON
968
First National Bank & Trust Co of Newtown
Pennsylvania
$1.98M -$1.68K -25 -0.1%
MJRIC
969
Mogy Joel R Investment Counsel
California
$1.98M -$20.1K -300 -1%
HH
970
Hilltop Holdings
Texas
$1.97M +$511K +7,618 +33%
FHA
971
Flagship Harbor Advisors
Massachusetts
$1.95M -$135K -2,018 -6%
SCA
972
Sippican Capital Advisors
Massachusetts
$1.94M -$13.6K -203 -0.7%
EFMC
973
Empire Financial Management Company
New York
$1.94M +$1.69M +25,265 +501%
DWMS
974
Dominguez Wealth Management Solutions
Virginia
$1.94M +$69.1K +1,031 +4%
SLA
975
Silver Lake Advisory
Utah
$1.93M -$81.9K -1,222 -4%

BMY Hedge Fund Activity: Q2 2023 in Review

2,481 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2023, worth a combined $102B — down 7.8% from $111B a quarter earlier.

Sellers outnumbered buyers: 163 funds closed out of BMY and 126 opened new positions — a net loss of 37 holders — while 1,065 trimmed existing stakes and 947 added.

The largest buyer was Capital International Investors, adding an estimated $528M. The largest seller was Bank of America, cutting an estimated $634M.

  • 2,481 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2023, down from 2,541 in Q1 2023.
  • Funds reported $102B of Bristol-Myers Squibb stock for Q2 2023, down 7.8% quarter-over-quarter.
  • 126 funds opened new Bristol-Myers Squibb positions in Q2 2023 and 163 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q2 2023 was Capital International Investors, an estimated $528M added.
  • The largest Bristol-Myers Squibb seller in Q2 2023 was Bank of America, an estimated $634M sold.

Based on aggregated 13F filings for Q2 2023.